For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Joji Nakayama, President and CEO
(Code no.: 4568, First Section of Tokyo, Osaka and Nagoya Stock Exchanges)
Please address inquiries to Toshiaki Sai, Corporate Officer,
Vice President, Corporate Communications Department
Telephone: +81-3-6225-1126
http://www.daiichisankyo.com/

About the News Report

TOKYO, Japan (December 7, 2011) – Today, some media in Japan reported that Daiichi Sankyo Co., Ltd. and GlaxoSmithKline plc will establish a vaccine-related joint venture company .

 

Our company consider vaccines to be a core business segment, and to strengthen our operations we constantly evaluate a wide range of strategic development opportunities.

 

However, today’s media reports are not based on any official announcement by the Daiichi Sankyo Group.